LEGN (LEGN) Stock Price & Analysis
LEGN (LEGN) rose 6.25% to USD 33.49 as of June 10, 2026 at 00:50 UTC, according to Nexqual real-time market data.
LEGN last closed at USD 31.52; the session ranged USD 31.34–33.53 on volume of 1,819,992 shares. Market capitalization is $6.22B, with a 52-week range of USD 16.24–45.3 (NMS). Source: Nexqual, June 10, 2026 at 00:50 UTC.
Key Statistics (as of June 10, 2026 at 00:50 UTC)
| Price | USD 33.49 |
|---|---|
| Change | ▲ 6.25% (up) |
| Previous Close | USD 31.52 |
| Open | USD 31.78 |
| Day Range | USD 31.34 – 33.53 |
| 52-Week Range | USD 16.24 – 45.3 |
| Volume | 1,819,992 shares |
| Market Cap | $6.22B |
| Exchange | NMS |
Technical Analysis (LEGN)
Nexqual's technical model rates LEGN "STRONG BUY" based on 5 bullish and 0 bearish signals across 124 daily candles, as of June 10, 2026 at 00:50 UTC.
| Overall Signal | STRONG BUY |
|---|---|
| RSI (14) | 59.85 (neutral) |
| vs SMA50 | Above (USD 25.34) |
| MACD | 2.2 (positive) |
Analyst Ratings (LEGN)
Wall Street analysts rate LEGN "Buy" based on 15 analysts, with a mean price target of USD 57.59 (range USD 27–86), per Nexqual as of June 10, 2026 at 00:50 UTC.
| Consensus Rating | Buy |
|---|---|
| Analyst Count | 15 |
| Mean Target | USD 57.59 |
| High Target | USD 86 |
| Low Target | USD 27 |
| Buy / Hold / Sell | 13 / 2 / 0 |
Earnings (LEGN)
| Next Earnings Date | 2026-08-10 |
|---|---|
| EPS Estimate | USD 0.28 |
| Revenue Estimate | $363.02M |
Recent Earnings History
| Quarter | Actual vs Estimate |
|---|---|
| 2025-12-31 | USD -0.16 vs est -0.19 ▲ beat |
| 2025-09-30 | USD -0.22 vs est -0.19 ▼ miss |
| 2025-06-30 | USD -0.68 vs est -0.23 ▼ miss |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financials & Fundamentals (LEGN)
| Total Revenue | $1.14B |
|---|---|
| Revenue Growth (YoY) | +56.50% |
| Gross Margin | +20.00% |
| Operating Margin | -16.32% |
| Profit Margin | -21.96% |
| ROE | -25.19% |
| Debt / Equity | 40.23 |
| Current Ratio | 2.13 |
| Total Cash | $834.60M |
| Total Debt | $389.30M |
| Free Cash Flow | $-55.77M |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Financial Health Score (LEGN)
Nexqual rates LEGN's overall financial health "Mixed" across five dimensions, as of June 10, 2026 at 00:50 UTC.
| Growth | Strong — Revenue +64% YoY (annual) |
|---|---|
| Profitability | Weak — Gross margin 20%, operating -16% |
| Balance Sheet | Strong — $835M cash vs $389M debt, net cash position |
| Cash Flow | Weak — FCF negative: -$56M, burning cash |
| Efficiency | Critical — ROE -25%, ROA -5.2% |
Ownership (LEGN)
| Insider Ownership | +1.31% |
|---|---|
| Institutional Ownership | +55.03% |
| Shares Outstanding | 185.74M |
| Float | 82.49M |
| Short % of Float | +19.64% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Leadership (LEGN)
LEGN is led by Ying Huang (age 52), CEO & Director, per Nexqual as of June 10, 2026 at 00:50 UTC.
| CEO & Director | Ying Huang (age 52) |
|---|---|
| Chief Financial Officer | Carlos Santos (age 53) |
| Vice President of Finance, Investor & Public Relations | Jessie Yeung (age 40) |
| President of Research & Development | Guowei Fang |
| Senior Vice President of Global Manufacturing & Supply | Birk Vanderweeen |
Major Backers & Investors (LEGN)
Notable institutional backers of LEGN include FMR, LLC, Fidelity, Deerfield Management Company, L.P, according to Nexqual as of June 10, 2026 at 00:50 UTC.
Active Investors
| Investor | Stake |
|---|---|
| FMR, LLC | 13.83% |
| Fidelity | 6.99% |
| Deerfield Management Company, L.P | 4.14% |
| Suvretta Capital Management, LLC | 4.08% |
| HHLR Advisors, LTD | 3.22% |
| Westfield Capital Management Co LP | 3.1% |
| Point72 Asset Management, L.P. | 2.09% |
| Artisan Partners Limited Partnership | 1.98% |
Index Funds (Passive)
| Fund | Stake |
|---|---|
| BlackRock | 3.05% |
Source: Nexqual, June 10, 2026 at 00:50 UTC.
Peers & Related Stocks
| Symbol | Name | Price | Change |
|---|---|---|---|
| PCVX | Vaxcyte, Inc. | USD 46.88 | ▼ 1.01% |
| RLAY | Relay Therapeutics, Inc. | USD 14.09 | ▲ 4.22% |
| KYMR | Kymera Therapeutics, Inc. | USD 76.91 | ▲ 3.75% |
| ZLAB | Zai Lab Limited | USD 16.65 | ▲ 0.18% |
| RVMD | Revolution Medicines, Inc. | USD 149.55 | ▲ 0.21% |
Data source: Nexqual — real-time market data, technical indicators, analyst consensus, earnings, SEC EDGAR filings. Last updated: June 10, 2026 at 00:50 UTC. This page is informational and not investment advice.